ANBIO BIOTECHNOLOGY LTD (NNNN) Fundamental Analysis & Valuation

NASDAQ:NNNN • KYG0367B1059

Current stock price

28.1 USD
+0.95 (+3.5%)
Last:

This NNNN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. NNNN Profitability Analysis

1.1 Basic Checks

  • NNNN had positive earnings in the past year.
  • NNNN had a negative operating cash flow in the past year.
  • In the past 5 years NNNN has always been profitable.
  • NNNN had a positive operating cash flow in 4 of the past 5 years.
NNNN Yearly Net Income VS EBIT VS OCF VS FCFNNNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 5M -5M 10M

1.2 Ratios

  • With an excellent Return On Assets value of 33.73%, NNNN belongs to the best of the industry, outperforming 97.87% of the companies in the same industry.
  • The Return On Equity of NNNN (33.83%) is better than 97.09% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 23.93%, NNNN belongs to the top of the industry, outperforming 98.06% of the companies in the same industry.
  • NNNN had an Average Return On Invested Capital over the past 3 years of 11.58%. This is significantly below the industry average of 27.75%.
  • The 3 year average ROIC (11.58%) for NNNN is below the current ROIC(23.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 33.73%
ROE 33.83%
ROIC 23.93%
ROA(3y)15.99%
ROA(5y)34.26%
ROE(3y)16.75%
ROE(5y)46.01%
ROIC(3y)11.58%
ROIC(5y)35.09%
NNNN Yearly ROA, ROE, ROICNNNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 77.10%, NNNN belongs to the best of the industry, outperforming 98.26% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NNNN has grown nicely.
  • NNNN's Operating Margin of 69.04% is amongst the best of the industry. NNNN outperforms 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of NNNN has grown nicely.
  • NNNN's Gross Margin of 89.00% is amongst the best of the industry. NNNN outperforms 90.50% of its industry peers.
  • In the last couple of years the Gross Margin of NNNN has grown nicely.
Industry RankSector Rank
OM 69.04%
PM (TTM) 77.1%
GM 89%
OM growth 3Y15.49%
OM growth 5YN/A
PM growth 3Y20.32%
PM growth 5YN/A
GM growth 3Y17.8%
GM growth 5YN/A
NNNN Yearly Profit, Operating, Gross MarginsNNNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. NNNN Health Analysis

2.1 Basic Checks

  • NNNN has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for NNNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NNNN Yearly Shares OutstandingNNNN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 50M 100M
NNNN Yearly Total Debt VS Total AssetsNNNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • NNNN has an Altman-Z score of 8146.87. This indicates that NNNN is financially healthy and has little risk of bankruptcy at the moment.
  • NNNN has a Altman-Z score of 8146.87. This is amongst the best in the industry. NNNN outperforms 100.00% of its industry peers.
  • NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8146.87
ROIC/WACCN/A
WACCN/A
NNNN Yearly LT Debt VS Equity VS FCFNNNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 344.45 indicates that NNNN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 344.45, NNNN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • A Quick Ratio of 344.45 indicates that NNNN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 344.45, NNNN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 344.45
Quick Ratio 344.45
NNNN Yearly Current Assets VS Current LiabilitesNNNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NNNN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 69.57% over the past year.
  • The earnings per share for NNNN have been decreasing by -13.70% on average. This is quite bad
  • The Revenue has decreased by -5.72% in the past year.
  • NNNN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.39% yearly.
EPS 1Y (TTM)69.57%
EPS 3Y-13.7%
EPS 5YN/A
EPS Q2Q%161.32%
Revenue 1Y (TTM)-5.72%
Revenue growth 3Y-28.39%
Revenue growth 5YN/A
Sales Q2Q%5.64%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NNNN Yearly Revenue VS EstimatesNNNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

2

4. NNNN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 122.17 indicates a quite expensive valuation of NNNN.
  • 88.95% of the companies in the same industry are more expensive than NNNN, based on the Price/Earnings ratio.
  • NNNN is valuated expensively when we compare the Price/Earnings ratio to 27.66, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 122.17
Fwd PE N/A
NNNN Price Earnings VS Forward Price EarningsNNNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNNN Per share dataNNNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

  • NNNN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NNNN Dividend Analysis

5.1 Amount

  • NNNN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NNNN Fundamentals: All Metrics, Ratios and Statistics

ANBIO BIOTECHNOLOGY LTD

NASDAQ:NNNN (4/22/2026, 10:42:22 AM)

28.1

+0.95 (+3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-07
Earnings (Next)N/A
Inst Owners4.85%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.23B
Revenue(TTM)13.23M
Net Income(TTM)10.20M
AnalystsN/A
Price TargetN/A
Short Float %0.07%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 122.17
Fwd PE N/A
P/S 93.21
P/FCF N/A
P/OCF N/A
P/B 40.9
P/tB 40.9
EV/EBITDA N/A
EPS(TTM)0.23
EY0.82%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.3
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.88561 (-93.29%)
Profitability
Industry RankSector Rank
ROA 33.73%
ROE 33.83%
ROCE 30.29%
ROIC 23.93%
ROICexc 39.53%
ROICexgc 39.53%
OM 69.04%
PM (TTM) 77.1%
GM 89%
FCFM N/A
ROA(3y)15.99%
ROA(5y)34.26%
ROE(3y)16.75%
ROE(5y)46.01%
ROIC(3y)11.58%
ROIC(5y)35.09%
ROICexc(3y)28.06%
ROICexc(5y)N/A
ROICexgc(3y)28.06%
ROICexgc(5y)N/A
ROCE(3y)14.66%
ROCE(5y)44.41%
ROICexgc growth 3Y-50.65%
ROICexgc growth 5YN/A
ROICexc growth 3Y-50.65%
ROICexc growth 5YN/A
OM growth 3Y15.49%
OM growth 5YN/A
PM growth 3Y20.32%
PM growth 5YN/A
GM growth 3Y17.8%
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 344.45
Quick Ratio 344.45
Altman-Z 8146.87
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3Y-13.7%
EPS 5YN/A
EPS Q2Q%161.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.72%
Revenue growth 3Y-28.39%
Revenue growth 5YN/A
Sales Q2Q%5.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.31%
EBIT growth 3Y-17.3%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-423.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-423.93%
OCF growth 3YN/A
OCF growth 5YN/A

ANBIO BIOTECHNOLOGY LTD / NNNN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ANBIO BIOTECHNOLOGY LTD?

ChartMill assigns a fundamental rating of 5 / 10 to NNNN.


What is the valuation status for NNNN stock?

ChartMill assigns a valuation rating of 2 / 10 to ANBIO BIOTECHNOLOGY LTD (NNNN). This can be considered as Overvalued.


What is the profitability of NNNN stock?

ANBIO BIOTECHNOLOGY LTD (NNNN) has a profitability rating of 8 / 10.


What are the PE and PB ratios of ANBIO BIOTECHNOLOGY LTD (NNNN) stock?

The Price/Earnings (PE) ratio for ANBIO BIOTECHNOLOGY LTD (NNNN) is 122.17 and the Price/Book (PB) ratio is 40.9.